Home / News

News

PetVivo Holdings, Inc. Announces Reverse Stock Split

PetVivo Holdings, Inc. Announces Reverse Stock Split

Petvivo Holdings Inc (OTCQB:PETV)

MINNEAPOLIS, MINNESOTA, USA, December 29, 2020 /EINPresswire.com/ -- PetVivo Holdings, Inc. (OTCQB: PETV) (the "Company") announced today that it has approved a 1-for-4 reverse stock split of its shares of common stock (“Reverse Stock Split”). PetVivo’s stockholders granted authority to the Board of Directors to effect this Reverse Stock Split of the Company’s common stock at its stockholder meeting held on September 22, 2020.


The Reverse Stock Split is scheduled to take effect today, December 29, 2020, at 5:00 p.m. ET (the “Effective Time”). The Company’s common stock will begin trading on a split-adjusted basis on Wednesday, December 30, 2020, under the new CUSIP number 716817408. The Company’s trading symbol will change to PETVD for a period of 20 business days, after which the D will be removed from the Company’s trading symbol and it will revert to the symbol of PETV.

John Lai, CEO of the Company, commented, “the purpose of this reverse stock split is to improve the Company’s capital structure related to listing requirements for a planned future listing of the Company’s common stock on the Nasdaq Capital Market® (“Nasdaq”).


Pursuant to this reverse stock split, each four (4) shares of the Company’s outstanding common stock, $.001 par value per share, will be automatically combined and converted into one (1) outstanding share of common stock, $.001 par value per share. As a result of this reverse stock split, the Company’s outstanding common shares will be reduced to approximately 6,718,252 shares.


This reverse stock split will affect all shareholders uniformly and accordingly will not alter any shareholders percentage interest and ownership in the Company’s equity, except to the extent that any shareholder would result in owning a fractional common share. Any fractional shares resulting from this reverse stock split will be rounded up to the next whole number of shares.


Shareholders of the Company holding their shares through a brokerage or street account will have their shares automatically adjusted to reflect this 1-for-4 reverse stock split. In the case of shareholders holding shares in certificated form, they need to exchange their present certificates for new stock certificates. Shareholders should direct any questions concerning this reverse stock split and exchange of their certificates to their broker or to the Company’s Transfer Agent, Equity Stock Transfer, at https://equitystock.com/contact.


Concurrent with the reverse stock split, the Company increased its authorized shares of common stock to 250 million shares (250,000,000), which increase was approved by the Company’s stockholders at the September 22, 2020 meeting.

About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQB: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.


PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of eighteen patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product Kush, a veterinarian-administered, intraarticular injection for the treatment of osteoarthritis in dogs and horses, is scheduled for expanded commercial sale later this year.



Forward-Looking commercial Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements, including the potential listing of the Company’s common stock on Nasdaq, are based on information currently available the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2020 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise

John Lai
Petvivo Holdings, Inc.
+1 952-405-6216

PetVivo Holdings, Inc. to exhibit at the American Association of Equine Practitioners Virtual Convention and Trade Show

PetVivo Holdings, Inc. to exhibit at the American Association of Equine Practitioners Virtual Convention and Trade Show

MINNEAPOLIS, Dec. 07, 2020 (GLOBE NEWSWIRE) -- OTCQB: (PETV) PetVivo Holdings, Inc. (www.petvivo.com) an emerging biomedical device company operating in the $19B veterinary market announced today it will be exhibiting at the American Association of Equine Practitioners (“AAEP”) Virtual Convention and Trade Show from December 5th to December 8th, 2020 that can be accessed online at https://convention.aaep.org/.

PetVivo is excited to meet with many of the more than 1,000 participants to talk about and introduce its lead product, KUSH®, a medical device injection of sterilized, hydrogel microparticles that are wet, slippery and spongy used in the treatment of lameness and other joint related afflictions, such as osteoarthritis. AAEP is the largest veterinary equine conference in the United States and plays host to many of the top industry professionals. As a highlight to the conference, PetVivo is hosting a presentation about joint afflictions and therapeutic treatments, which includes information about its own cartilage mimicking medical device, KUSH®. The presentation will feature a keynote speaker and expert in equine health, Tracy Turner, DVM, MS, Dipl. ACVS, Dipl. ACVSMR, who will provide beneficial insight on common lameness afflictions found in horses and the therapies he has used to treat such injured animals.

“I am incredibly excited to participate in the presentation hosted by PetVivo entitled “Kush® - a Promising New Treatment for Joint Problems” to share my thoughts and insights regarding equine lameness and the beneficial treatments for such afflictions,” explained Dr. Tracy Turner.

Conference Details:

American Association of Equine Practitioners Virtual Convention and Trade Show

Dates:

Sunday, December 6, 2020 9:00am – 5:00pm

Monday, December 7, 2020 9:00am – 5:00pm

Tuesday, December 8, 2020 9:00am – 4:00pm

Location: Virtual

For more information about PetVivo, Inc. and Kush, please contact info1@petvivo.com or visit https://petvivo.com/

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCQB: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.

PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of eighteen patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product Kush, a veterinarian-administered, intraarticular injection for the treatment of osteoarthritis in dogs and horses, is scheduled for expanded commercial sale later this year.

CONTACT:

John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com 
(952) 405-6216

 

Forward-Looking commercial Statements:

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar matters that are not historical facts. These statements may be preceded by, followed by, or include the words “aim,” “anticipate,” “believe,” “estimate, “expect,” “forecast,” “intend,” “likely,” “outlook,” “plan,” “potential,” “project,” “projection,” “seek,” “can,” “could,” “may,” “should,” “would,” “will,” the negatives thereof and other words and terms of similar meanings. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. There is no assurance that any forward-looking statements will materialize. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

PetVivo Holdings, Inc. Announces Sponsored Research Agreement with Colorado State University for Osteoarthritis Treatment Study.

PetVivo Holdings, Inc. Announces Sponsored Research Agreement with Colorado State University for Osteoarthritis Treatment Study.

MINNEAPOLIS, Nov. 12, 2020 (GLOBE NEWSWIRE) -- OTCQB: (PETV) PetVivo Holdings, Inc. (OTCQB: PETV) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets is pleased to announce the entry into a sponsored research agreement with Colorado State University (“CSU”) College of Veterinary Medicine and Biomedical Sciences to engage in a clinical study involving the treatment of osteoarthritis in canines through the administration of PetVivo’s proprietary medical device, KUSH®.

The treatment of osteoarthritis in canines through the administration of PetVivo’s proprietary medical device, KUSH®.

Felix Duerr, DVM, associate professor of small animal orthopedics, will serve as Principal Investigator for the research project. Dr. Duerr established and now oversees CSU’s Orthopedic Medicine and Mobility program. His clinical interests include sports medicine and rehabilitation, and minimally invasive surgery, including arthroscopy.

“The study designed by the team is novel and he hopes the research will lead to new ways to treat osteoarthritis, which affects up to 20% of all dogs, no matter the age,” said Dr. Duerr.

KUSH is a medical device that is administered by intraarticular injection in afflicted joints of animals, such as dogs and horses, for the treatment of osteoarthritis. The product is intended to provide a lubricious cushion between the bones to reinforce cartilage. A primary objective of PetVivo is to commercialize beneficial medical device products, such as KUSH, to further enhance the lives and happiness of companion animals and their owners.

About PetVivo Holdings, Inc.

For more information about PetVivo and Kush, please contact info1@petvivo.com or visit https://petvivo.com/

PetVivo Holdings Inc. (OTCQB: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.

PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of eighteen patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product Kush, a veterinarian-administered, intraarticular injection for the treatment of osteoarthritis in dogs and horses, is scheduled for expanded commercial sale later this year.

CONTACT:

John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
5251 Edina Industrial Blvd.
Minneapolis, MN 55439
www.petvivo.com

Forward-Looking commercial Statements:

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar matters that are not historical facts. These statements may be preceded by, followed by, or include the words “aim,” “anticipate,” “believe,” “estimate, “expect,” “forecast,” “intend,” “likely,” “outlook,” “plan,” “potential,” “project,” “projection,” “seek,” “can,” “could,” “may,” “should,” “would,” “will,” the negatives thereof and other words and terms of similar meanings. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. There is no assurance that any forward-looking statements will materialize. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.